New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
19:49 EDTACRXAcelRX met primary endpoint in Phase 3 trial
AcelRx Pharmaceuticals announced it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on November 15. AcelRx management will host an conference call at 8:00 a.m. EST to discuss the Phase 3 top-line results.
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
17:58 EDTACRXAcelRx trading halted, pending news
Subscribe for More Information
15:43 EDTACRXAcelRx volatility elevated into July 27 PDUFA date for Zalviso
Subscribe for More Information
09:25 EDTACRXOn The Fly: Pre-market Movers
Subscribe for More Information
05:24 EDTACRXAcelRx confirms July 27 PDUFA date for Zalviso
Subscribe for More Information
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use